Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Raised to “Strong-Buy” at HC Wainwright

02 Oct 2026, 11:36 by Mitch Edgeman · The Markets Daily

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) was upgraded by equities researchers at HC Wainwright to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks reports.

A number of other brokerages also recently issued reports on GLUE. Guggenheim reissued a “buy” rating and issued a $28.00 price objective on shares of Monte Rosa Therapeutics in a research note on Tuesday, August 25th. Wells Fargo & Company decreased their target price on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Weiss Ratings downgraded Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Jefferies Financial Group reissued a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Finally, TD Cowen upgraded Monte Rosa Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

Check Out Our Latest Report on GLUE

Monte Rosa Therapeutics Stock Down 5.6%

GLUE opened at $11.26 on Thursday. Monte Rosa Therapeutics has a twelve month low of $7.24 and a twelve month high of $25.77. The company has a fifty day moving average of $14.88 and a 200-day moving average of $17.76. The stock has a market cap of $960.59 million, a PE ratio of -6.40 and a beta of 1.37.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. The firm had revenue of $8.97 million during the quarter, compared to analyst estimates of $12.91 million. Sell-side analysts anticipate that Monte Rosa Therapeutics will post -1.04 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the sale, the insider directly owned 67,845 shares of the company’s stock, valued at $1,581,466.95. The trade was a 8.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 6.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GLUE. BlackRock Inc. bought a new stake in Monte Rosa Therapeutics during the 2nd quarter worth approximately $165,603,000. Jupiter Topco LLC purchased a new position in shares of Monte Rosa Therapeutics during the second quarter valued at approximately $25,965,000. Opaleye Management Inc. bought a new stake in Monte Rosa Therapeutics during the second quarter worth $18,029,000. Dimensional Fund Advisors LP raised its holdings in shares of Monte Rosa Therapeutics by 83.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,041,372 shares of the company’s stock valued at $17,125,000 after purchasing an additional 473,005 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of Monte Rosa Therapeutics during the second quarter valued at about $15,778,231. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics News Roundup

Here are the key news stories impacting Monte Rosa Therapeutics this week:

Positive Sentiment: Positive Phase 1 results: MRT-8102 produced robust and sustained NEK7 degradation at all tested once-daily doses. In obese participants with elevated cardiovascular risk, several disease-related biomarkers—including HMGB1, calprotectin, S100A12, serum amyloid A and IL-1β—fell to levels comparable with those observed in healthy volunteers. Monte Rosa Announces Positive MRT-8102 GFORCE-1 Results
Positive Sentiment: Favorable safety profile: Four weeks of treatment and four weeks of follow-up produced no serious adverse events, adverse-event rates comparable with placebo, and no evidence of increased infection risk. Monte Rosa plans Phase 2 studies in coronary artery disease, gout and hidradenitis suppurativa. Monte Rosa Plans Mid-Stage Trials for MRT-8102
Positive Sentiment: New analyst support: HC Wainwright initiated coverage with a Buy rating and a $25 price target, providing additional external validation of Monte Rosa’s molecular-glue platform and development pipeline. HC Wainwright Initiates Coverage
Neutral Sentiment: The data measure biomarker normalization rather than clinical cardiovascular outcomes. Investors will likely focus on whether Phase 2 trials confirm efficacy, durability and safety in larger patient populations.
Negative Sentiment: The weaker share performance suggests some investors may be taking profits or adopting a more cautious view after the initial data reaction, particularly because MRT-8102 remains an early-stage asset and Phase 2 execution will require additional time and funding.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.